Long-term performance of beta-propiolactone-treated nonviable homograft for aortic valve replacement and right ventricular outflow tract reconstruction.
The long-term performance of beta-propiolactone-treated homografts was clearly different between operative survivors of aortic valve replacement (n = 27) and those of right ventricular outflow tract reconstruction (n = 11). The reoperation-free survival rate at 20 years was 14.8 +/- 6.8 (standard error)% in the former and 77.8 +/- 13.9% in the latter. Even a nonviable aortic homograft can be favorably accepted as a material for right ventricular outflow tract reconstruction in contrast to the aortic position.
Matsuki
O
O
First Department of Surgery, Osaka University Medical School, Japan.
Kadoba
K
K
Nakata
S
S
Shirakura
R
R
Nakano
S
S
Matsuda
H
H
Kawashima
Y
Y
D000328:Adult; D001021:Aortic Valve / Q000637:transplantation*; D005260:Female; D006085:Graft Survival; D006349:Heart Valve Diseases / Q000401:mortality / Q000601:surgery; D006801:Humans; D008297:Male; D011420:Propiolactone; D012086:Reoperation; D015996:Survival Rate; D013771:Tetralogy of Fallot / Q000401:mortality / Q000601:surgery; D013997:Time Factors; D014694:Ventricular Outflow Obstruction / Q000401:mortality / Q000601:surgery*
D011420:Propiolactone